When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...
Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...
The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities. A research team from ...
Thank you for your article on antisense 1 and for letting us know that the subject is very much alive. Although antisense is an "RNA therapeutic" in that the target is mRNA, actually in almost all ...
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...
An international team of scientists has designed a new type of therapy to target the mutant toxic RNA that causes myotonic ...
Cold Spring Harbor Laboratory researchers have reported that a bespoke antisense oligonucleotide can disrupt alternative ...
So far, 2013 has been a good year for antisense technology. In fact, it’s been great. In January the FDA OK’d Isis Pharmaceuticals’ Kynamro™ (mipomersen sodium), the only currently marketed antisense ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q3z4pf/pharmasphere) has announced the addition of the "PharmaSphere ...
Researchers from Osaka University have developed a novel approach to target nicotinamide N-methyltransferase (NNMT), an enzyme implicated in cancer progression, using antisense oligonucleotides (ASOs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results